|
1
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cha C, Fong Y, Jarnagin WR, Blumgart LH
and DeMatteo RP: Predictors and patterns of recurrence after
resection of hepatocellular carcinoma. J Am Coll Surg. 197:753–758.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guo W, He X, Li Z and Li Y: Combination of
transarterial chemoembolization (TACE) and radiofrequency ablation
(RFA) vs. surgical resection (SR) on survival outcome of early
hepatocellular carcinoma: A meta-analysis. Hepatogastroenterology.
62:710–714. 2015.PubMed/NCBI
|
|
4
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, De Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shirasaka T, Shimamato Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hatano H, Kobayashi S, Nagano H, Tomokuni
A, Tomimaru Y, Murakami M, Marubashi S, Eguchi H, Takeda Y,
Tanemura M, et al: A case of successful multimodal treatment for
combined hepatocellular and cholangiocarcinoma with portal venous
tumor thrombus. Gan To Kagaku Ryoho. 36:2374–2376. 2009.(In
Japanese). PubMed/NCBI
|
|
8
|
Nakamura M, Nagano H, Wada H, Noda T, Ota
H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, et
al: A case of hepatocellular carcinoma with multiple lung, spleen,
and remnant liver metastasis successfully treated by combination
chemotherapy with the novel oral DPD-inhibiting chemotherapeutic
drug S-1 and interferon-alpha. J Gastroenterol. 41:1120–1125. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suganuma T, Terauchi R, Shikina A, Tanaka
M, Aozasa S, Utsunomiya K, Fujino K, Ito H, Okada K, Tsuda T and
Hase K: A case of hepatocellular carcinoma with bone metastasis
responding to concurrent TS-1/low-dose cisplatin (CDDP) therapy and
radiotherapy. Gan To Kagaku Ryoho. 31:781–784. 2004.(In Japanese).
PubMed/NCBI
|
|
10
|
Furuse J, Okusaka T, Kaneko S, Kudo M,
Nakachi K, Ueno H, Yamashita T and Ueshima K: Phase I/II study of
the pharmacokinetics, safety and efficacy of S-1 in patients with
advanced hepatocellular carcinoma. Cancer Sci. 101:2606–2611. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kudo M, Moriguchi M, Numata K, Hidaka H,
Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Okusaka T, et al: A
randomized, double-blind, placebo-controlled phase III study of S-1
in patients with sorafenib-refractory advanced hepatocellular
carcinoma (S-CUBE). J Clin Oncol. 33 Supple:abstr 40182015.
|
|
12
|
Salonga D, Danenberg KD, Johnson M,
Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman
L, Diasio RB and Danenberg PV: Colorectal tumors responding to
5-fluorouracil have low gene expression levels of dihydropyrimidine
dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Clin Cancer Res. 6:1322–1327. 2000.PubMed/NCBI
|
|
13
|
Leichman CG, Lenz HJ, Leichman L,
Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and
Danenberg PV: Quantitation of intratumoral thymidylate synthase
expression predicts for disseminated colorectal cancer response and
resistance to protracted-infusion fluorouracil and weekly
leucovorin. J Clin Oncol. 15:3223–3229. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lenz HJ, Danenberg KD, Leichman CG,
Florentine B, Jonston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV
and Leichman LP: p53 and thymidylate synthase expression in
untreated stage II colon cancer: Associations with recurrence,
survival, and site. Clin Cancer Res. 4:1227–1234. 1998.PubMed/NCBI
|
|
15
|
Kuramochi H, Hayashi K, Uchida K, Miyakura
S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K and
Danenberg PV: 5-fluorouracil-related gene expression levels in
primary colorectal cancer and corresponding liver metastasis. Int J
Cancer. 119:522–526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Johnston SJ, Ridge SA, Cassidy J and
McLeod HL: Regulation of dihydropyrimidine dehydrogenase in
colorectal cancer. Clin Cancer Res. 5:2566–2570. 1999.PubMed/NCBI
|
|
17
|
Peng Y, Qi X and Guo X: Child-pugh versus
MELD score for the assessment of prognosis in liver cirrhosis: A
systematic review and meta-analysis of observational studies.
Medicine (Baltimore). 95:e28772016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nii A, Shimada M, Ikegami T, Harino Y,
Imura S, Morine Y, Kanemura H, Arakawa Y and Sugimoto K:
Significance of dihydropyrimidine dehydrogenase and thymidylate
synthase mRNA expressions in hepatocellular carcinoma. Hepatol Res.
39:274–281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takahashi T, Yoshida H, Mamada Y, Taniai
N, Mizuguchi Y, Shimizu T, Kakinuma D, Ishikawa Y, Akimaru K,
Sugisaki Y and Tajiri T: Profiling of fluorouracil-related genes by
microdissection technique in hepatocellular carcinoma.
Hepatogastroenterology. 54:1612–1616. 2007.PubMed/NCBI
|
|
21
|
Lenz HJ, Hayashi K, Salonga D, Danenberg
KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S,
Leichman LP and Leichman CG: p53 point mutations and thymidylate
synthase messenger RNA levels in disseminated colorectal cancer: An
analysis of response and survival. Clin Cancer Res. 4:1243–1250.
1998.PubMed/NCBI
|
|
22
|
Metzger R, Leichman CG, Danenberg KD,
Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H,
Laine L, et al: ERCC1 mRNA levels complement thymidylate synthase
mRNA levels in predicting response and survival for gastric cancer
patients receiving combination cisplatin and fluorouracil
chemotherapy. J Clin Oncol. 16:309–316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Edler D, Glimelius B, Hallström M,
Jakobsen A, Johnston PG, Magnsson I, Ragnhammar P and Blomgren H:
Thymidylate synthase expression in colorectal cancer: A prognostic
and predictive marker of benefit from adjuvant fluorouracil-based
chemotherapy. J Clin Oncol. 20:1721–1728. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koumarianou A, Tzeveleki I, Mekras D,
Eleftheraki AG, Bobos M, Wirtz R, Fountzilas E, Valavanis C,
Xanthakis I, Kalogeras KT, et al: Prognostic markers in early-stage
colorectal cancer: Significance of TYMS mRNA expression. Anticancer
Res. 34:4949–4962. 2014.PubMed/NCBI
|
|
25
|
Zhao HY, Ma GW, Zou BY, Li M, Lin SX, Zhao
LP, Guo Y, Huang Y, Tian Y, Xie D and Zhang L: Prognostic
significance of thymidylate synthase in postoperative non-small
cell lung cancer patients. Onco Targets Ther. 7:1301–1310. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu
H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N,
Matsukuma N, et al: Efficacy, safety, and survival factors for
sorafenib treatment in Japanese patients with advanced
hepatocellular carcinoma. Oncology. 84:108–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
